Market Closed -
Japan Exchange
02:30:00 2025-07-14 am EDT
5-day change
1st Jan Change
1,032.00 JPY
+1.88%
+13.91%
+83.30%
Sumitomo Pharma Secures 233 Billion Yen Syndicated Loan to Refinance Debt
Published on 03/26/2025 at 06:31,
updated on 03/26/2025 at 06:32
Jefferies Adjusts Sumitomo Pharma's Price Target to 1,300 Yen From 1,200 Yen, Keeps at Buy
Jul. 09
MT
Sawai Group Holdings Co., Ltd. completed the acquisition of FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd..
Jun. 29
CI
Sumitomo Pharma Transfers Key US Product Assets to Strengthen Oversight
Jun. 26
MT
Japan's Nikkei retreats from 4-month high as US-Iran tensions weigh
Jun. 19
RE
Japan's Nikkei retreats from 4-month high as threat of US involvement in Iran conflict looms
Jun. 18
RE
Sumitomo Pharma Co., Ltd., Q3 2025 Earnings Call, Jan 31, 2025
Jun. 13
Japan's Nikkei falls as US stock futures decline, firmer yen weighs
Jun. 12
RE
Japan's Nikkei rises for third session as government backs debt market
Jun. 10
RE
Japanese shares rise for third day on tech optimism, JGB support
Jun. 09
RE
Knight Therapeutics and Sumitomo Pharma Enter into Exclusive Licensing Agreements to Commercialize Sumitomo?S Canadian Portfolio
Jun. 05
CI
Knight Therapeutics Seals Deal With Sumitomo Pharma to Commercialize Canadian Portfolio
Jun. 05
MT
Knight Therapeutics And Sumitomo Pharma Enter Into Exclusive Licensing Agreements To Commercialize Sumitomo'S Canadian Portfolio
Jun. 05
RE
Knight Therapeutics Brief: Knight and Sumitomo Pharma Entering Into Exclusive Licensing Agreements To Commercialize Sumitomo's Canadian Portfolio
Jun. 05
MT
Japan's Nikkei surges as trade optimism lifts tech; Toyota Industries plunges
Jun. 03
RE
Tranche Update on Roivant Sciences Ltd.'s Equity Buyback Plan announced on April 2, 2024.
May. 29
CI
Sumitomo Pharma Forms New Entity for Asian Business Spinoff
May. 29
MT
Poxel SA Announces New Clinical and Scientific Data on TWYMEEG® to Be Presented at the 68th Annual Meeting of the Japan Diabetes Society
May. 28
CI
Jefferies Adjusts Sumitomo Pharma's Price Target to 1,200 Yen From 1,100 Yen, Keeps at Buy
May. 14
MT
Sumitomo Pharma Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2026
May. 13
CI
Sumitomo Pharma Co., Ltd. Announces Board Changes
May. 13
CI
Japan's Nikkei snaps 7-day winning streak as US tariff worries weigh
May. 07
RE
Japan's Nikkei heavy as US tariff woes counter China optimism
May. 06
RE
Trade, Central Banks Lift Asia Stocks in Thin Holiday Trading
May. 01
MT
Sumitomo Pharma Raises Fiscal 2025 Forecast on Strong Drug Sales
Apr. 29
MT
Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2025
Apr. 28
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
4506: Dynamic Chart
Sumitomo Pharma Co Ltd, formerly Sumitomo Dainippon Pharma Co Ltd, is a Japan-based pharmaceutical company. The Company operates its business through four segments. The Japan segment is engaged in the manufacture, purchase, and sale of ethical drugs. The North American segment is engaged in the manufacture, purchase, and sale of ethical drugs and conducts research and development in the areas of oncology, urology, respiratory disease, and regenerative cell medicine. The China segment is engaged in the manufacture (small packaged products) and sale of ethical pharmaceuticals. The Overseas Others segment is engaged in the manufacture and sale of ethical pharmaceuticals in Europe. The segment also purchase and sell ethical pharmaceuticals in Southeast Asia and Taiwan, as well as provide information and collection activities for the Company's products. Other business includes manufacturing, purchasing, and sales of food ingredients, food additives and chemical product materials.
More about the company
Last Close Price
1,013.00 JPY
Average target price
797.50 JPY
Spread / Average Target
-21.27%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
Select your edition
All financial news and data tailored to specific country editions